Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 26;305(1):46–53. doi: 10.1148/radiol.220543

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the Radiological Society of North America, Inc.

This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Graphs show changes in (A) temporal cortical thickness and (B) number of lymph nodes over time between the recipients of a messenger RNA (mRNA) vaccine (BNT162b2 [n = 37] and mRNA-1273 [n = 3]) and a vector vaccine (ChAdOx1 nCoV-19 [n = 51]). (A) Lymphadenopathy was most commonly observed in the first 2 weeks of mRNA vaccine administration, with larger cortical thickness (mean, 5.26 mm ± 0.2). Lymphadenopathy was most commonly observed 2–4 weeks after vector vaccination, with lower cortical thickness (mean, 4.35 mm ± 0.3). The cortical thickness of lymph nodes gradually decreased over time regardless of vaccine type; nonetheless, its thickness was higher in recipients of the mRNA vaccine than in recipients of the vector vaccine. (B) The number of lymph nodes was higher in recipients of the mRNA vaccine than in recipients of the vector vaccine (mean, 6.03 nodes ± 0.3 vs 3.9 nodes ± 0.3) and gradually decreased regardless of vaccine type. A linear mixed model was established to estimate the time effect on cortical thickness and number of lymph nodes. — Graphs show changes in (A) temporal cortical thickness and (B) number of lymph nodes over time between the recipients of a messenger RNA (mRNA) vaccine (BNT162b2 [n = 37] and mRNA-1273 [n = 3]) and a vector vaccine (ChAdOx1 nCoV-19 [n = 51]). (A) Lymphadenopathy was most commonly observed in the first 2 weeks of mRNA vaccine administration, with larger cortical thickness (mean, 5.26 mm ± 0.2). Lymphadenopathy was most commonly observed 2–4 weeks after vector vaccination, with lower cortical thickness (mean, 4.35 mm ± 0.3). The cortical thickness of lymph nodes gradually decreased over time regardless of vaccine type; nonetheless, its thickness was higher in recipients of the mRNA vaccine than in recipients of the vector vaccine. (B) The number of lymph nodes was higher in recipients of the mRNA vaccine than in recipients of the vector vaccine (mean, 6.03 nodes ± 0.3 vs 3.9 nodes ± 0.3) and gradually decreased regardless of vaccine type. A linear mixed model was established to estimate the time effect on cortical thickness and number of lymph nodes.